BridgeBio Pharma, Inc.

NASDAQ:BBIO

Biotechnology

Healthcare
$78.01 +1.13%

+$0.75 today

Market cap
$15.20B
Beta
0.97
P/E (TTM)
-18.1
EPS (TTM)
-$3.73
52W Low $40.19High $84.94

Volume 3.55M

Average 2.49M

BBIO Net Income

Bottom-line profit, the starting point for calculating cash from operations.

BridgeBio Pharma, Inc.NASDAQ: BBIO

Net Income · Q2 FY2026 · quarter ended Jun 2026

Net income declines year over year

Q2 FY2026 net income of $155.89M (cash outflow) fell 15.2% year over year, behind the -11.4% change in trailing-twelve-month net income. Sequentially, it fell 6.4% from the prior quarter. Over 3 fiscal years it compounded at +14.4% a year.

Context

  • Net income amounted to 144.4% of revenue in FY2025, down 100.5 pp from a year earlier.
  • Net income grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 13 analysts of -$478.53M (-34.0%) for the fiscal year ending Dec 2026, a slowdown from the +33.4% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
-$155.89M-6.4% QoQ
Last fiscal yearDec 2025
-$724.93M+33.4% YoY
LTMJun 2026
-$695.45M-11.4% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-15.2%-41.8%-26.7 pp
1 year+33.4%-34.0%-67.4 pp
3-year CAGR+14.4%——
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(724.93M) USD
Year-over-year change
-33.4%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How BBIO compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -11.4% is the 9th highest of 11, against a peer median of +41.1%.
  • Net income amounts to 97.5% of revenue for BBIO, versus a peer median of 65.3%.
BBIO Competitors
Net Income for BBIO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026$27.6B USD+3808.4%+35.1%2.7%
ASNDAscendis Pharma A/SLTM Sep 2026€890.37M EUR+482.2%-27.9%73.7%
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 2026$807.99M USD+353.2%—16.8%
BBIOBridgeBio Pharma, Inc.LTM Jun 2026$695.45M USD-11.4%+14.4%97.5%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$608.92M USD+10.8%-6.7%91.0%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$546.15M USD+113.1%+12.2%56.9%
DNLIDenali Therapeutics Inc.LTM Jun 2026$511.45M USD+6.8%+16.3%14191.2%
SRRKScholar Rock Holding CorporationLTM Sep 2026$413.61M USD+17.0%+41.1%72563.2%
TVTXTravere Therapeutics, Inc.LTM Sep 2026$146.22M USD+65.1%-57.4%22.5%
MAZEMaze Therapeutics, Inc.LTM Mar 2026$122.54M USD-335.9%+4.5%612.7%
PTCTPTC Therapeutics, Inc.LTM Jun 2026$38.38M USD-106.1%—3.8%
Peer median (excluding BBIO) —+41.1%+8.4%65.3%

Competitors are the stored peer set for BBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(586.45M)(484.65M)(643.2M)(543.35M)(724.93M)
Depreciation & Amortization5.84M6.77M6.49M6.08M5.43M
Deferred Income Tax(30.93M)0000
Stock-Based Compensation99.51M91.56M095.8M133.02M
Change in Working Capital(4.4M)28.08M5.06M32.04M(51.06M)
Accounts Receivables(19.75M)15.17M15.33M(2.97M)(134.72M)
Inventory19.75M000(25.31M)
Accounts Payables2.83M(349K)2.78M1.51M26.61M
Other Working Capital(7.23M)13.26M(13.05M)33.5M82.36M
Other Non-Cash Items18.5M(61.25M)103.93M(111.3M)191.63M
Operating Cash Flow(497.93M)(419.49M)(527.72M)(520.73M)(445.91M)
Capital Expenditures(48.25M)(6.32M)(1.31M)(933K)(1.1M)
Acquisitions (Net)(35M)00(140K)0
Purchases of Investments(643.28M)(193.06M)(137.26M)(88.4M)(28.2M)
Sales of Investments477.04M532.52M193.11M158.23M11M
Other Investing Activities48.65M118.5M(503K)(7.98M)(6.19M)
Investing Cash Flow(200.83M)453.15M54.03M60.78M(24.49M)
Debt Repayment1.08B(20.49M)0476.58M385.5M
Common Stock Issued04.85M449.81M314.74M34.15M
Common Stock Repurchased(204.75M)(1.56M)(6.88M)(7.53M)(48.28M)
Dividends Paid00000
Other Financing Activities(138.49M)4.06M8.61M(35.34M)(12.08M)
Financing Cash Flow736.45M(13.13M)451.54M748.46M359.29M
Effect of Forex Changes00000
Net Change in Cash37.69M20.52M(22.15M)288.51M(111.1M)
Free Cash Flow(546.18M)(425.82M)(529.03M)(521.66M)(447.01M)

BridgeBio Pharma, Inc.

NASDAQ:BBIO

Intrinsic Alpha fair value

Locked

Current Price

$78.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.